Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Better options available for MDR

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 20, 2021 9:30pm

145 Views

Post# 32846070

RE:RE:RE:Better options available for MDR

Well it's maybe a little more complex than that. Depends if they pick up the virus from somebody under ART treatmentthe, passed on virus may only be a subset of all the virus in the original person and might therefore have more limited MDR issues but generally the answer is yes.

qwerty22 wrote:

Yes.

Lee430 wrote: Question for the science members, if someone is infected with HIV from an advanced MDR individual will they be at the same MDR level? It seems like that’s the way it would work, sure would be a horrible way to start one’s battle with HIV.